United States - English - NLM (National Library of Medicine)

tmig inc. - fenamiphos (unii: h4no3l2hbe) (pyridoxine - unii:kv2jz1bi6z), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), selenium (unii: h6241uj22b) (selenium - unii:h6241uj22b), chromium (unii: 0r0008q3jb) (chromium - unii:0r0008q3jb), zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - fenamiphos 100 mg - t-support max is indicated for the clinical dietary management of the individuals with thyroid conditions. hyperthyroidism hyperthyroidism the name given to overproduction of thyrozine, causes extreme nervousness and irritability, increased heart rate and blood pressure, and weight loss. underproduction of thyrozine, or hypothyroidism, results in dry skin, brittle nails, and a lack of energy in adults. goiter, which is actually an enlarged thyroid, is a sign of thyroid insufficiency. in infants, hypothyroidism can be devastating, inhibiting physical development and causing irreversible mental retardation. hypothyroidism hypothyroidism is a condition in which the thyroid gland fails to function adequately, resulting in reduced levels of thyroid hormone in the body. cretinism is a type of hypothyroidism that occurs at birth and results in stunted physical growth and mental development. severe hypothyroidism is called myxedema. interactions with drugs before using this product, tell your doctor or pharmacist

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; iron oxide black; polysorbate 20; purified water; ethyl lactate; sorbitan oleate; titanium dioxide; peg-40 hydrogenated castor oil; glycerol; tricaprin; lecithin - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: gelatin; titanium dioxide; tricaprin; sorbitan oleate; lecithin; purified water; ethyl lactate; polysorbate 20; iron oxide black; peg-40 hydrogenated castor oil; glycerol - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: gelatin; iron oxide black; ethyl lactate; lecithin; polysorbate 20; glycerol; sorbitan oleate; purified water; tricaprin; peg-40 hydrogenated castor oil; titanium dioxide - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

etac anz pty ltd - 45052 - transport wheelchair, collapsible - transport wheelchair attendant driven collapsible

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (unii: flv5i5w26r) (haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen - unii:flv5i5w26r) - haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen 10 ug in 0.5 ml - acthib® is a vaccine indicated for the prevention of invasive disease caused by haemophilus influenzae (h. influenzae) type b. acthib is approved for use in children 2 months through 5 years of age. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any h. influenzae type b or tetanus toxoid-containing vaccine or any component of the vaccine is a contraindication to administration of acthib vaccine [see description (11)] . acthib is not approved for use in individuals 6 years of age and older. no human or animal data are available to assess vaccine-associated risks in pregnancy. acthib is not approved for use in individuals 6 years of age and older. human or animal data are not available to assess the impact of acthib on milk production, its presence in breast milk, or its effects on the breastfed infant. safety and effectiveness of acthib have not been established in infants below the age of 6 weeks and children and adolescents 6 years of age and older [see dosage and administration (2.1)] .

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - ornipressin, quantity: 5 iu/ml - injection, solution - excipient ingredients: sodium acetate; glacial acetic acid; sodium chloride; water for injections - local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem plastic surgery: hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc obstetrics/gynaecology: vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy. ent surgery: tonsillectomy, submucous resection of septum, myringoplasty etc. other types of surgery: neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar).

Australia - English - Department of Health (Therapeutic Goods Administration)

hurst & co pty ltd - 62773 - general specimen collection kit ivd, transport medium - transport swabs are intended for the collection of biological samples for subsequent microbiological analysis

Philippines - English - FDA (Food And Drug Administration)

agio pharamceuticals limited - drug - silver sulfadiazine - topisulfa

Philippines - English - FDA (Food And Drug Administration)

agio pharamceuticals limited - drug - fusidic acid - fucelcid